Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents

Nascimento da Cruz, Anne Cecília; Brondani, Dalci José; I´talo de Santana, Temístocles; Oliveira da Silva, Lucas; da Oliveira Borba, Elizabeth Fernanda; de Faria, Antônio Rodolfo; Ferreira Cavalcanti  de Albuquerque, Julianna; Piessard, Sylvie; Matos Ximenes, Rafael; Baratte, Blandine; Bach, Stéphane; Ruchaud, Sandrine; Bezerra Mendonça Junior, Francisco Jaime; Bazin, Marc-Antoine; Montenegro Rabello, Marcelo; Hernandes, Marcelo Zaldini; Marchand, Pascal; Gonçalves da Silva, Teresinha

doi:10.3390/ph12040169

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessArticle

Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents

Departamento de Antibióticos, Centro de Biociências, Universidade Federal de Pernambuco, Recife, PE, 50740-520, Brazil

Departamento de Ciências Farmacêuticas, Centro de Ciências da Saúde, Universidade Federal de Pernambuco, Recife, PE, 50740-520, Brazil

Université de Nantes, Cibles et Médicaments des Infections et du Cancer, IICiMed, EA 1155, Nantes, F-44000, France

⁴

Sorbonne Université, CNRS, USR3151, « Protein phosphorylation and human diseases » Unit, Station Biologique, Roscoff, F-29688, France

⁵

Sorbonne Université, CNRS, FR2424, Kinase Inhibitor Specialized Screening Facility - KISSf, Station Biologique, Roscoff, F-29688, France

⁶

Laboratory of Synthesis and Drug Delivery, Department of Biological Sciences, State University of Paraiba, João Pessoa, PB, 58071-160, Brazil

Authors to whom correspondence should be addressed.

Pharmaceuticals 2019, 12(4), 169; https://doi.org/10.3390/ph12040169

Received: 10 October 2019 / Revised: 14 November 2019 / Accepted: 14 November 2019 / Published: 17 November 2019

(This article belongs to the Special Issue Recent Contributions in Medicinal Chemistry Within European GP2A Network)

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

Fourteen arylsemicarbazone derivatives were synthesized and evaluated in order to find agents with potential anticancer activity. Cytotoxic screening was performed against K562, HL-60, MOLT-4, HEp-2, NCI-H292, HT-29 and MCF-7 tumor cell lines. Compounds 3c and 4a were active against the tested cancer cell lines, being more cytotoxic for the HL-60 cell line with IC₅₀ values of 13.08 μM and 11.38 μM, respectively. Regarding the protein kinase inhibition assay, 3c inhibited seven different kinases and 4a strongly inhibited the CK1δ/ε kinase. The studied kinases are involved in several cellular functions such as proliferation, migration, cell death and cell cycle progression. Additional analysis by flow cytometry revealed that 3c and 4a caused depolarization of the mitochondrial membrane, suggesting apoptosis mediated by the intrinsic pathway. Compound 3c induced arrest in G1 phase of the cell cycle on HL-60 cells, and in the annexin V assay approximately 50% of cells were in apoptosis at the highest concentration tested (26 μM). Compound 4a inhibited cell cycle by accumulation of abnormal postmitotic cells at G1 phase and induced DNA fragmentation at the highest concentration (22 μM). View Full-Text

Keywords: semicarbazones; cytotoxicity; anticancer activity; cell cycle; apoptosis; kinase inhibition

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

Supplementary File 1:
PDF-Document (PDF, 3115 KiB)

Share and Cite

MDPI and ACS Style

Nascimento da Cruz, A.C.; Brondani, D.J.; I´talo de Santana, T.; Oliveira da Silva, L.; da Oliveira Borba, E.F.; de Faria, A.R.; Ferreira Cavalcanti de Albuquerque, J.; Piessard, S.; Matos Ximenes, R.; Baratte, B.; Bach, S.; Ruchaud, S.; Bezerra Mendonça Junior, F.J.; Bazin, M.-A.; Montenegro Rabello, M.; Hernandes, M.Z.; Marchand, P.; Gonçalves da Silva, T. Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents. Pharmaceuticals 2019, 12, 169. https://doi.org/10.3390/ph12040169

AMA Style

Nascimento da Cruz AC, Brondani DJ, I´talo de Santana T, Oliveira da Silva L, da Oliveira Borba EF, de Faria AR, Ferreira Cavalcanti de Albuquerque J, Piessard S, Matos Ximenes R, Baratte B, Bach S, Ruchaud S, Bezerra Mendonça Junior FJ, Bazin M-A, Montenegro Rabello M, Hernandes MZ, Marchand P, Gonçalves da Silva T. Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents. Pharmaceuticals. 2019; 12(4):169. https://doi.org/10.3390/ph12040169

Chicago/Turabian Style

Nascimento da Cruz, Anne Cecília, Dalci José Brondani, Temístocles I´talo de Santana, Lucas Oliveira da Silva, Elizabeth Fernanda da Oliveira Borba, Antônio Rodolfo de Faria, Julianna Ferreira Cavalcanti de Albuquerque, Sylvie Piessard, Rafael Matos Ximenes, Blandine Baratte, Stéphane Bach, Sandrine Ruchaud, Francisco Jaime Bezerra Mendonça Junior, Marc-Antoine Bazin, Marcelo Montenegro Rabello, Marcelo Zaldini Hernandes, Pascal Marchand, and Teresinha Gonçalves da Silva. 2019. "Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents" Pharmaceuticals 12, no. 4: 169. https://doi.org/10.3390/ph12040169

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Biological Evaluation of Arylsemicarbazone Derivatives as Potential Anticancer Agents

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI